DCC-3009 – KIT and PDGFRA inhibitor
Advanced gastrointestinal stromal tumor (GIST)
About This Program
DCC-3009 is an investigational switch-control KIT and PDGFRA inhibitor designed to act against known clinically relevant primary and secondary GIST-driving mutations.
DCC-3009 is being investigated in a Phase 1/2 study evaluating the safety, tolerability, and efficacy in patients with advanced GIST.
To learn more about this study, click here.